CSIMarket
 


Ovid Therapeutics Inc   (OVID)
Other Ticker:  
 

Cumulative Ovid Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

OVID's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

OVID Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 58.39 % 10.5 % -0.2 % -42.15 % -56.36 %
Y / Y Cash & cash equivalent Growth -17.96 % -36.86 % -36.69 % -29.41 % -31.34 %
Quick Ratio for Trailing Twelve Months Period 12.42 14.83 17 18.96 17.96
Total Ranking # 78 # 141 # # #
Seq. Current Liabilities Growth 37.49 % -19.11 % 55.43 % -8.37 % -4.08 %
Seq. Cash & cash equivalent Growth 21.55 % -9.79 % -18.01 % -8.75 % -6.45 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to growth in Current Liabilities in the IV. Quarter to $10 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 12.42 below Ovid Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Ovid Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about OVID
Quick Ratio OVID in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 33
Sector # 52
S&P 500 # 86


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
15.91 8.74 4.01
(Dec 31 2021)   (Dec 31 2020)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Rayzebio Inc   34.09 
Prometheus Biosciences Inc   33.43 
Moonlake Immunotherapeutics  32.43 
Inhibitor Therapeutics Inc   30.02 
Morphic Holding inc   29.63 
Ars Pharmaceuticals Inc   29.51 
Design Therapeutics Inc   29.08 
Cohbar Inc   27.36 
Cyteir Therapeutics Inc   27.13 
Terns Pharmaceuticals Inc   25.94 
Atossa Therapeutics Inc   25.85 
Theseus Pharmaceuticals Inc   25.84 
Eliem Therapeutics Inc   25.00 
Astria Therapeutics inc   24.41 
Briacell Therapeutics Corp   24.30 
Bright Minds Biosciences Inc   24.16 
Belite Bio Inc  23.58 
Xenon Pharmaceuticals Inc   23.53 
Eqrx Inc   23.06 
Acelyrin Inc   22.77 
Aprea Therapeutics Inc   22.56 
Lixte Biotechnology Holdings Inc   21.56 
Sio Gene Therapies Inc   21.43 
Janux Therapeutics Inc   21.10 
Pmv Pharmaceuticals Inc   20.92 
Savara Inc   20.70 
Edgewise Therapeutics inc   20.64 
Nuvalent Inc   20.36 
Kura Oncology Inc   20.11 
Akero Therapeutics Inc   19.46 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com